Drug Type Small molecule drug |
Synonyms 1-(1H-indol-4-yloxy)-3-(isopropylamino)propan-2-ol, 1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)-propan-2-ol, 1-(1H-indol-4-yloxy)-3-[(1-methylethyl)amino]propan-2-ol + [8] |
Target |
Action antagonists |
Mechanism β-adrenoceptors antagonists(Beta adrenergic receptors antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (26 Aug 1972), |
Regulation- |
Molecular FormulaC14H20N2O2 |
InChIKeyJZQKKSLKJUAGIC-UHFFFAOYSA-N |
CAS Registry13523-86-9 |
Start Date26 Nov 2021 |
Sponsor / Collaborator [+1] |
Start Date07 Feb 2014 |
Sponsor / Collaborator |
Start Date01 Jan 2013 |
Sponsor / Collaborator |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Arrhythmias, Cardiac | China | - | 01 Jan 1995 |
Hypertension | China | - | 01 Jan 1995 |
Angina Pectoris | Japan | 19 Jun 1980 | |
Essential Hypertension | Japan | 31 Aug 1976 | |
Tachycardia, Sinus | Japan | 26 Aug 1972 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Not Applicable | - | 24 | (Citalopram and Pindolol) | ngiqqyilee(lrtayszplj) = aacahhdoqo bytrrdxmla (xgniyohtmr, hsmnjglhxt - xuwfeazlyn) View more | - | 09 Oct 2024 | |
Placebo (Placebo) | ngiqqyilee(lrtayszplj) = jjnzzeisah bytrrdxmla (xgniyohtmr, yxqntqrzpx - hketukflro) View more | ||||||
Phase 2 | 30 | Citalopram + Pindolol | zpamjxseqz(fozpglhyvv) = xrpljmqvfo zcxjojivaz (imfczetqud ) | Positive | 01 Jul 2011 | ||
Citalopram + Placebo | zpamjxseqz(fozpglhyvv) = xgwzigftvg zcxjojivaz (imfczetqud ) |